Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients
read more
Citations
Cancer epigenetics reaches mainstream oncology
Statistical methods in medical research
Oxidative Stress and DNA Methylation in Prostate Cancer
The epigenetic promise for prostate cancer diagnosis
Global methylation profiling for risk prediction of prostate cancer
References
The Statistical Analysis of Failure Time Data.
Statistical Methods in Cancer Research
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
The Statistical Analysis of Failure Time Data
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Related Papers (5)
Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Frequently Asked Questions (9)
Q2. What have the authors contributed in "Promoter methylation in apc, runx3, and gstp1 and mortality in prostate cancer patients" ?
The authors investigated the association between promoter methylation in a priori selected genes and survival in two independent large series of prostate cancer patients. The authors followed up with two cohorts of patients ( 216 patients diagnosed in 1982 to 1988 and 243 patients diagnosed in 1993 to 1996 ) diagnosed at one hospital pathology ward in Turin, Italy.
Q3. What is the methylation of the promoter region of a gene?
In addition, repressor complexes may be attracted to sites of promoter methylation, leading to the formation of inactive chromatin structures.
Q4. How many men received a PSA test in the 1990s?
It has been estimated that, each year, more than 10% of men older than 50 years received a PSA test at the end of the 1990s in Northern Italy.
Q5. What is the effect of opportunistic PSA screening?
The decrease in age at diagnosis and increase in survival that the authors observed in the 1990s cohort is consistent with an effect of opportunistic PSA screening.
Q6. What was the effect of methylation on the survival of patients in the 1990s?
To understand whether a lack of cancer cells in some tissue slices biased their estimates, the authors provisionally restricted survival analyses to patients positive for methylation in GSTP1, for whom tumor cells were most likely sufficiently represented, and patients who underwent biopsy, where all available tissue was paraffin embedded in one single block.
Q7. How many years did the methylation in the 1990s cohort affect the survival of the patients?
In both cohorts, pair-wise comparisons revealed that methylation in each gene was independent from methylation in the other two genes (P .25).A2 4 6 12108 14Cu mul ativ ePr osta teC ance r Mor talit yFollow-Up Duration (years)00.20.40.60.81.0 APC in 1980s cohortGray’s test P = .112 4 6 12108 14Cu mul ativ ePr osta teC ance r Mor talit yFollow-Up Duration (years)00.20.40.60.81.0 APC in 1990s cohortGray’s test P = .02Unmethylation MethylationB2 4 6 12108 14
Q8. What was the adequacy of the -globin gene?
The authors extracted genomic DNA from 3 to 5 (10- m thick) sequential sections of PETs and checked for adequacy by PCR amplification of the -globin gene.
Q9. What was the grade of the tumors in the 1980s cohort?
In those cases, the authors used the information on tumor grade that was available in the pathology report; well-differentiated tumors were translated to a Gleason score of 6 or less, moderately differentiated tumors corresponded to a score of 7, and poorly differentiated tumors had a score of 8 .